Literature DB >> 27756910

Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Ai-Jun Pan1,2, Qing Mei2, Ying Ye1,3,4, Hong-Ru Li5, Bao Liu2, Jia-Bin Li1,3,4,6.   

Abstract

The purpose of this study was to validate the mutant selection window (MSW) hypothesis in vitro and in vivo with Escherichia coli and Pseudomonas aeruginosa exposed to fosfomycin. Two standard strains of Gram-negative bacteria, those are E. coli ATCC 25922 and P. aeruginosa ATCC 27853, were exposed to fosfomycin at concentrations below MIC, between the MIC and the mutant prevention concentration (MPC), and above the MPC in Luria-Bertani broth and in a tissue-cage infection model, respectively. With the in vitro time-kill studies, there were bacterial re-growth and emergence of resistance thereafter for both strains at antibiotic concentrations of × 4, × 8 and × 16 MIC. In our animal model, the loss in susceptibility of P. aeruginosa at fosfomycin concentrations fluctuated between the lower and upper boundaries of the MSW. In contrast, the emergence of resistant mutants of E. coli was not observed in vivo, regardless of fosfomycin dosage. Interestingly, the in vitro-isolated resistant mutants of E. coli showed a decreased growth rate compared with the susceptible parental strains, whereas no fitness cost in P. aeruginosa was observed. The emergence of antibiotic resistance is shaped by several factors. MSW theory may not apply to all antimicrobial-pathogen combinations. Before it can be used as a framework for the design of antimicrobial therapy, the existence of the window must be demonstrated not only in vitro but also in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27756910     DOI: 10.1038/ja.2016.124

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  32 in total

1.  [Microorganisms isolated from outpatient urine samples and antimicrobial susceptibility over a 12-year period].

Authors:  F C Rodríguez López; F Franco-Alvarez de Luna; R M Gordillo Urbano; A Ibarra González; M Casal Román
Journal:  Rev Esp Quimioter       Date:  2005-06       Impact factor: 1.553

Review 2.  Optimizing drug exposure to minimize selection of antibiotic resistance.

Authors:  Sara K Olofsson; Otto Cars
Journal:  Clin Infect Dis       Date:  2007-09-01       Impact factor: 9.079

3.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

4.  Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus.

Authors:  Beibei Liang; Nan Bai; Yun Cai; Rui Wang; Karl Drlica; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

5.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 6.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

7.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

8.  In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.

Authors:  Clare C Walsh; Michelle P McIntosh; Anton Y Peleg; Carl M Kirkpatrick; Phillip J Bergen
Journal:  J Antimicrob Chemother       Date:  2015-07-24       Impact factor: 5.790

Review 9.  Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.

Authors:  Drosos E Karageorgopoulos; Rui Wang; Xu-Hong Yu; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2011-11-16       Impact factor: 5.790

10.  Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis.

Authors:  Li-guang Liu; Yu-lin Zhu; Li-fen Hu; Jun Cheng; Ying Ye; Jia-bin Li
Journal:  J Antibiot (Tokyo)       Date:  2013-08-28       Impact factor: 2.649

View more
  5 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and Resistant Enterococcus.

Authors:  Yaowen Li; Yu Peng; Na Zhang; Huiping Liu; Jun Mao; Yisong Yan; Shuaishuai Wang; Guang Yang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Infect Drug Resist       Date:  2022-08-30       Impact factor: 4.177

3.  Nisin Influence on the Antimicrobial Resistance Ability of Canine Oral Enterococci.

Authors:  Eva Cunha; Rita Janela; Margarida Costa; Luís Tavares; Ana Salomé Veiga; Manuela Oliveira
Journal:  Antibiotics (Basel)       Date:  2020-12-10

4.  Synergistic Combination of Linezolid and Fosfomycin Closing Each Other's Mutant Selection Window to Prevent Enterococcal Resistance.

Authors:  Lifang Jiang; Na Xie; Mingtao Chen; Yanyan Liu; Shuaishuai Wang; Jun Mao; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-02-09       Impact factor: 5.640

Review 5.  Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.

Authors:  George G Zhanel; Michael A Zhanel; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-06-25       Impact factor: 2.471

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.